Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Ehospitalization Econfirmed COVID (any severity) E

COVID-19 prophylaxis (excluding children) meta-analysis

C4591031- first boost
  NCT04955626		 RCTfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)low
5081/5044 conclusif demonstrated-85%
Pfizer/BioNTech Booster study
  NCT04713553		 RCTfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)NA
-/- no results
COVI3 OBSfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)NA
-/- suggested -84%
McConeghy OBSfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)NA
-/- suggested -87% -43% -46%
Kislaya OBSfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)NA
-/- suggested -62%
Bar-On OBSfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)NA
-/- suggested -82%
Accorsi OBSfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)NA
-/- no results
Abu-Raddad OBSfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)NA
-/- suggested -44%
Arbel OBSfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)serious
758118/85090 suggested -81%
Barda OBSfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)NA
728321/728321 suggested -73% -84%
Mattiuzzi OBSfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)NA
-/- suggested -87% -62% -59%
Patalon OBSfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)NA
-/- suggested -83% -76%
Tenforde OBSfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)NA
-/- suggested -74% -47%
Patalon OBSfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)NA
-/- suggested -71%

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons